Biotech companies present pipeline updates at Citigroup summit

Several biotechnology companies participated in Citigroup’s Biopharma Back to School Summit in September 2026, providing updates on drug pipelines and clinical developments.

Protagonist Therapeutics discussed its recent drug approvals and the long-term development process behind its products. Separately, the company’s CEO, Dinesh Patel, executed a pre-arranged Rule 10b5-1 trading plan to sell 54,174 shares at an average price of $145.87.

Olema Pharmaceuticals provided updates on its lead asset, palazestrant, a complete estrogen receptor antagonist for ER-positive HER2-negative breast cancer. The company expects top-line data from its Phase III trials in the first quarter.

EyePoint, Inc. presented details on its drug delivery technology for the back of the eye, specifically its lead product DURAVYU, and noted upcoming Phase III results. Seaport Therapeutics, a newly public neuroscience company, also presented on its core technology and applications within the field.